|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Allegra CJ, Jessup JM, Somerfield MR, et
al: American Society of Clinical Oncology provisional clinical
opinion: Testing for KRAS gene mutations in patients with
metastatic colorectal carcinoma to predict response to
anti-epidermal growth factor receptor monoclonal antibody therapy.
J Clin Oncol. 27:2091–2096. 2009. View Article : Google Scholar
|
|
3
|
Jimeno A, Messersmith WA, Hirsch FR,
Franklin WA and Eckhardt SG: KRAS mutations and sensitivity to
epidermal growth factor receptor inhibitors in colorectal cancer:
practical application of patient selection. J Clin Oncol.
27:1130–1136. 2009. View Article : Google Scholar
|
|
4
|
Sartore-Bianchi A, Bencardino K,
Cassingena A, et al: Therapeutic implications of resistance to
molecular therapies in metastatic colorectal cancer. Cancer Treat
Rev. 36(Suppl 3): S1–S5. 2010. View Article : Google Scholar
|
|
5
|
De Roock W, De Vriendt V, Normanno N,
Ciardiello F and Tejpar S: KRAS, BRAF, PIK3CA, and PTEN mutations:
Implications for targeted therapies in metastatic colorectal
cancer. Lancet Oncol. 12:594–603. 2011.PubMed/NCBI
|
|
6
|
Artale S, Sartore-Bianchi A, Veronese SM,
et al: Mutations of KRAS and BRAF in primary and matched metastatic
sites of colorectal cancer. J Clin Oncol. 26:4217–4219. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kosakowska EA, Stec R, Charkiewicz R,
Skoczek M and Chyczewski L: Molecular differences in the KRAS gene
mutation between a primary tumor and related metastatic sites -
case report and a literature review. Folia Histochem Cytobiol.
48:597–602. 2010.
|
|
8
|
Baldus SE, Schaefer KL, Engers R, Hartleb
D, Stoecklein NH and Gabbert HE: Prevalence and heterogeneity of
KRAS, BRAF, and PIK3CA mutations in primary colorectal
adenocarcinomas and their corresponding metastases. Clin Cancer
Res. 16:790–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ashworth T: A case of cancer in which
cells similar to those in the tumours were seen in blood after
death. Aust Med J. 14:146–149. 1869.
|
|
10
|
Gerges N, Rak J and Jabado N: New
technologies for the detection of circulating tumour cells. Br Med
Bull. 94:49–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alunni-Fabbroni M and Sandri MT:
Circulating tumour cells in clinical practice: Methods of detection
and possible characterization. Methods. 50:289–297. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lustberg M, Jatana KR, Zborowski M and
Chalmers JJ: Emerging technologies for CTC detection based on
depletion of normal cells. Recent Results Cancer Res. 195:97–110.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baas JM, Krens LL, Guchelaar HJ, Morreau H
and Gelderblom H: Concordance of predictive markers for EGFR
inhibitors in primary tumors and metastases in colorectal cancer: A
review. Oncologist. 16:1239–1249. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bossard C, Küry S, Jamet P, et al:
Delineation of the infrequent mosaicism of KRAS mutational status
in metastatic colorectal adenocarcinomas. J Clin Pathol.
65:466–469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bouchahda M, Karaboué A, Saffroy R, et al:
Acquired KRAS mutations during progression of colorectal cancer
metastases: Possible implications for therapy and prognosis. Cancer
Chemother Pharmacol. 66:605–609. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wicha MS and Hayes DF: Circulating tumor
cells: not all detected cells are bad and not all bad cells are
detected. J Clin Oncol. 29:1508–1511. 2011. View Article : Google Scholar : PubMed/NCBI
|
